Navigation Links
Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma
Date:6/4/2008

Results of phase I/II study highlighted in oral presentation at conference

on malignant lymphoma

LUGANO, Switzerland, June 5 /PRNewswire-FirstCall/ -- At the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland data were presented from a phase I/II investigator-sponsored clinical trial of Yttrium-90 Ibritumomab Tiuxetan (90Y-Zevalin) combined with the novel expanded porphyrin motexafin gadolinium (MGd). The greatest benefit of this investigational regimen was observed in rituximab-refractory follicular lymphoma patients, who experienced rapid responses and a high rate of durable complete responses (CR). In this subset of patients (n=14), 64 percent experienced a complete response with a median estimated time to progression (TTP) of 14 months. These results compare favorably to prior published data of single agent Zevalin in terms of CR and TTP. The investigators concluded that MGd given with Zevalin does not appear to increase hematologic or other toxicities. Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States. MGd is under development by Pharmacyclics, Inc.

"Zevalin is approved for relapsed follicular non-Hodgkin's lymphoma based on superior overall and complete response rates compared to rituximab, including rituximab-refractory follicular non-Hodgkin's lymphoma where Zevalin resulted in a 74 percent overall response rate with 15 percent complete and unconfirmed complete responses," said James A. Bianco, M.D., President and CEO of CTI. "The results of the study suggest that addition of MGd may enhance the effectiveness of radioimmunotherapy with Zevalin. Further studies using this combination in patients with follicular or diffuse large B-cell lymphoma are warranted."

About the Study

Of the 30 patients enrolled on this study, 28 are currently evaluable. All patients were rituximab-refractory. No dose limiting toxicity was seen. No grade 4 non-he
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novel Technology Breaks Through Cancer Pain
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
6. NIST team develops novel method for nanostructured polymer thin films
7. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
8. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
9. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
10. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
11. GenVault and the National Center for Forensic Science to Present Novel Technology for Room Temperature Storage of RNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... 2014 W. R. Grace & ... the REVELERIS® Prep purification system , a ... and other researchers to perform both flash and ... , With the REVELERIS® Prep purification system, researchers ... modes with a simple touch of the screen, ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Group (USA), Inc. (the "Company" or "Tiens", NYSE AMEX: ... announced financial results for the third quarter and nine months ... of 2010 was $10.4 million, compared to $9.4 million for the ... 30, 2010 was $30.0 million, compared to $48.2 million for the ...
... 15, 2010 Celladon Corp., a biopharmaceutical company ... treatments for cardiovascular diseases, today announced that 12-month ... of MYDICAR® demonstrated significant improvements in clinical outcomes ... patients treated with the genetically-targeted enzyme replacement therapy. ...
... Webcast to Discuss ASSERT Clinical Trial Data ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 2Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 4Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 5Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 6Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 7Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 8Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 9Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 3Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 4Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 2Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 3Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 4Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 5Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 6Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 7
(Date:7/30/2014)... ALBANY, New York , July 30, 2014 ... up-to-date research on Global Government Biometric Systems ... Analysis. The Global Biometric Systems Market ... global biometric systems market over the next ten ... industry, using detailed market size forecasts. ...
(Date:7/30/2014)... about what they eat, the Food and Drug Administration ... Nutrition Facts label found on nearly every food product ... Engineering News (C&EN), the weekly news magazine of ... and the fight that has ensued. , Britt Erickson, ... the Nutrition Facts label has remained largely the same ...
(Date:7/30/2014)... interest in neuroscience. A large number of genes ... Wallerian degeneration: transcription factor activation, immune response, myelin ... in the distal segment of the sciatic nerve ... gene expression between the proximal and distal segments ... Nantong University, China used microarrays to analyze changes ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... trauma, say from a sabertooth tiger attack, meant immediate death ... to survive severe injury caused by a car crash, gunshot ... does not know what to do when it survives an ... evolution. Nearly one third of the time, mechanisms in place ...
... that the ability of plants to defend themselves by accumulating ... some insects, and that such adaptation potentially echoes in the ... evolve to deal with high levels of the toxic element. ... and colleagues there and at the University of California, Berkeley, ...
... and proteins that explain how animals discern bitter from sweet, ... mutant fruit flies prefer eating sugar over sugar laced with ... that a single protein missing from the fly-equivalent of our ... the caffeine as if it were not there. , "No, ...
Cached Biology News:PNAS study reveals why organs fail following massive trauma 2PNAS study reveals why organs fail following massive trauma 3PNAS study reveals why organs fail following massive trauma 4PNAS study reveals why organs fail following massive trauma 5New moth variety disarms plants guarded by selenium 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 3
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
...
... the revolutionary Luminex 100 System delivers a ... real time enhancing your operational efficiency. This ... Luminex 100, the XY Platform, and the ... you to simultaneously assay up to 100 ...
Biology Products: